Communiqués Aprea Therapeutics, Inc.

Actions

APRE

US03836J2015

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 25/08/2026			Varia. 5j.	Varia. 1 janv.
0,9499 ^USD	+17,97%		+41,35%	+11,36%

12/08	Aprea Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
12/08	Aprea Therapeutics, Inc. : Wedbush toujours positif	ZM

Communiqués

12/08	Aprea Therapeutics Announces Second Quarter 2026 Financial Results	AQ
30/07	Aprea Therapeutics Provides ACESOT-1051 Program Update for WEE1 Inhibitor APR-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026	AQ
01/06	Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors	AQ
13/05	Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update	AQ
21/04	Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting	AQ
06/04	Frazier Life Sciences Appoints Christian Schade as Senior Advisor	AQ
01/04	Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement	AQ
30/03	Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement	AQ
30/03	Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial	AQ
16/03	Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update	AQ
18/02	Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial	AQ
17/02	Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference	AQ
13/02	Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response Cancer Therapeutics, Paving Way for Pipeline Growth	AQ
12/02	Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth	AQ
04/02	Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor	AQ
29/01	Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan	AQ
29/01	Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules	AQ
18/12	Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026	AQ
09/12	Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules	AQ
12/11	Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update	AQ
24/10/25	Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051	AQ
15/10/25	Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies	AQ
14/10/25	Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics	AQ
28/08/25	Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference	AQ
12/08/25	Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update	AQ